Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients

Despite new antivirals are being approved against SARS-CoV-2 they suffer from significant constraints and are not indicated for hospitalized patients, who are left with few antiviral options. Repurposed drugs have previously shown controversial clinical results and it remains difficult to understand...

Descripción completa

Detalles Bibliográficos
Autores principales: De Forni, Davide, Poddesu, Barbara, Cugia, Giulia, Chafouleas, James, Lisziewicz, Julianna, Lori, Franco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648746/
https://www.ncbi.nlm.nih.gov/pubmed/36355808
http://dx.doi.org/10.1371/journal.pone.0276751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648746/
https://www.ncbi.nlm.nih.gov/pubmed/36355808
http://dx.doi.org/10.1371/journal.pone.0276751

Ejemplares similares